Menopause

The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.

Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.

Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.

Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.

Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.

JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.

Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.

Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.

NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.

Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.

JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.

Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.

Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.

Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.

A systematic review found transdermal nitroglycerin may modestly reduce hot flashes, but evidence remains limited.

The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.

The Menopause Society's 2026 meeting in San Diego will tackle estrogen avoidance, cancer survivorship, mood, and sleep.

Real-world fezolinetant (Veozah) sleep data help ob-gyns counsel patients hesitant about hormone therapy, according to Marla Shapiro, CM, MDCM.

ACOG issued its most comprehensive menopause guidance, grading treatments for VMS, sleep, and mood symptoms.

Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.

Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Fezolinetant (Veozah) was linked to objective and patient-reported sleep gains in OPTION-VMS, with no new safety signals observed.

Wen Shen, MD, explains how clinicians can counter menopause misinformation from social media and steer patients toward evidence-based resources.

Wen Shen, MD, outlines when to treat perimenopausal symptoms and which history-taking red flags should prompt earlier bone and cardiovascular screening or referral.